Evidence map›Paper›PMID 26253079›Full record

ReviewPathogens and disease2015

What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.

Shelly Bolotin, Eric T Harvill, Natasha S Crowcroft

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pathogens and disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Development and validation of a robust multiplex serological assay to quantify antibodies specific to pertussis antigens.Biologicals : journal of the International Association of Biological Standardization · 2019
    Article
  10. Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  11. Article
  12. Review
  13. Review
  14. Use of a 40-day rolling incidence to monitor pertussis in Nova Scotia, 2015.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2017
    Article
  15. Bordetella pertussis: new concepts in pathogenesis and treatment.Current opinion in infectious diseases · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Shelly BolotinPublic Health Ontario, Toronto, Ontario, Canada Dalla Lana School of Public Health, University of Toronto, 155 College St., Toronto, Ontario M5T 3M7, Canada shelly.bolotin@oahpp.ca.
Eric T HarvillVeterinary and Biomedical Science, Pennsylvania State University, 115 Henning Building, University Park, PA 16802 Lee Kong Chian School of Medicine and Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798.
Natasha S CrowcroftPublic Health Ontario, Toronto, Ontario, Canada Dalla Lana School of Public Health, University of Toronto, 155 College St., Toronto, Ontario M5T 3M7, Canada Department of Laboratory Medicine and Pathobiology, University of Toronto, Medical Sciences Building, 1 Kings College Circle, # 2331, Toronto, Ontario M5S 1A8, Canada.
Canada Research Chairs · CANanyang Technological University · SGPublic Health Ontario · CA

Funding

Evolution of the Bordetellae from Commensals to PathogensR01GM083113 · NIGMS · PENNSYLVANIA STATE UNIVERSITY, THE · PI HARVILL, ERIC T · 2008 to 2011
$2.1M
The Microbiota Pathogen CompetitionR01GM113681 · NIGMS · UNIVERSITY OF GEORGIA · PI HARVILL, ERIC T · 2015 to 2018
$1.3M
In vivo vaccine-driven evolution in Bordetella pertussisR21AI116186 · NIAID · UNIVERSITY OF GEORGIA · PI HARVILL, ERIC T · 2015 to 2016
$411k
Bordetella sp. Versus MicrobiotaR56AI107016 · NIAID · PENNSYLVANIA STATE UNIVERSITY, THE · PI HARVILL, ERIC T · 2014 to 2014
$377k
NIAID NIH HHS AI107016NIAID NIH HHS AI116186NIAID NIH HHS R21 AI116186NIAID NIH HHS R56 AI107016NIGMS NIH HHS GM083113NIGMS NIH HHS GM113681NIGMS NIH HHS R01 GM083113NIGMS NIH HHS R01 GM113681
6 · The paper itself

Abstract

Pertussis (whooping cough) is a respiratory disease caused by the bacterium Bordetella pertussis. Despite the implementation of immunization programs and high vaccine coverage in most jurisdictions, pertussis is still one of the most common vaccine-preventable diseases, suggesting that the current vaccines and immunization schedules have not been sufficiently effective. Several factors are thought to contribute to this. The acellular pertussis vaccine that has been used in many jurisdictions since the 1990s is less effective than the previously used whole-cell vaccine, with immunity waning over time. Both whole-cell and acellular pertussis vaccines are effective at reducing disease severity but not transmission, resulting in outbreaks in vaccinated cohorts. In this review, we discuss various limitations of the current approaches to protection from pertussis and outline various options for reducing the burden of pertussis on a population level.

Indexed as

Bordetella pertussisDisease Transmission, InfectiousDrug DiscoveryHumansPertussis VaccineWhooping CoughPertussis VaccineimmunityPertussistransmissionvaccinevaccine effectivenesswhooping cough

Identifiers

PMID26253079
PMCPMC4626586
OpenAlexW1054027755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.